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ABSTRACT
Chronic pain is a common source of morbidity
in many patient populations worldwide. There
are growing concerns about the potential side
effects of currently prescribed medications and
a continued need for effective treatment. Related to these concerns, peripheral nerve stimulation has been regaining popularity as a
potential treatment modality. Peripheral nerve
stimulation components include helically
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coiled electrical leads, which direct an applied
current to afferent neurons providing sensory
innervation to the painful area. In theory, the
applied current to the peripheral nerve will alter
the large-diameter myelinated afferent nerve
fibers, which interfere with the central processing of pain signals through small-diameter
afferent fibers at the level of the spinal cord.
Multiple studies have shown success in the use
of peripheral nerve stimulation for acute postsurgical pain for orthopedic surgery, including
post total knee arthroplasty and anterior cruciI. Urits
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ate ligament surgery, and chronic knee pain.
Many studies have investigated the utility of
peripheral nerve stimulation for the management of chronic shoulder pain. Peripheral nerve
stimulation also serves as one of the potential
non-pharmacologic therapies to treat back pain
along with physical therapy, application of
transcutaneous electrical neurostimulation
unit, radiofrequency ablation, epidural steroid
injections, permanently implanted neurostimulators, and surgery. Studies regarding back
pain treatment have shown that peripheral
nerve stimulation led to significant improvement in all pain and quality-of-life measures
and a reduction in the use of opioids. Further
studies are needed as the long-term risks and
benefits of peripheral nerve stimulation have
not been well studied as most information
available on the effectiveness of peripheral
nerve stimulation is based on shorter-term
improvements in chronic pain.

Numerous studies have demonstrated
success with peripheral nerve stimulation
in the treatment of acute post-surgical
pain following orthopedic surgery,
including total knee arthroplasty and
anterior cruciate ligament reconstruction,
and chronic knee pain.
Peripheral nerve stimulation has been
shown to significantly improve all pain
and quality-of-life measures and to
decrease the use of opioids in studies
examining back pain treatment.
Additional research is needed to
determine the long-term risks and benefits
of peripheral nerve stimulation, as the
majority of available information on its
effectiveness is based on short-term
improvements in chronic pain.

INTRODUCTION
Keywords: Chronic pain; Knee pain; Back pain;
Shoulder pain; Opioid reduction; PNS
Key Summary Points
Chronic pain is a significant cause of
morbidity in a wide variety of patient
populations throughout the world.
Concerns about the potential side effects
of currently prescribed medications
continue to grow, as does the need for
effective treatment.
Peripheral nerve stimulation has been
regaining popularity as a potential
treatment modality in response to these
concerns. Components of peripheral
nerve stimulation include helically coiled
electrical leads that direct an applied
current to afferent neurons that innervate
the painful area sensory.

Chronic pain is a common source of morbidity
in many patient populations worldwide. Studies
link chronic pain with limitations to mobility,
interference with daily activities, dependence
on opioid analgesics, and psychiatric illness [1].
With growing concerns about potential side
effects of currently prescribed medications and
a continued need for effective treatment, the
medical community is open to alternatives that
provide safe and effective measures to control
patient pain. Related to these concerns,
peripheral nerve stimulation (PNS) has been
regaining popularity as a potential treatment
modality.
This article is based on previously conducted
studies and does not contain any new studies
with human participants or animals performed
by any of the authors.
History of Peripheral Nerve Stimulation
The concept of PNS for the management of pain
originated in the first century AD with the discovery that torpedo fish produce electrical discharges that were noted to provide relief of pain
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[2, 3]. Following this discovery, several attempts
were made to produce man-made electrical
nerve stimulators that replicate the effects
observed from torpedo fish. The earliest concept
of peripheral nerve stimulation as we know it
today was introduced in 1967 [4]. In this study,
the authors demonstrated temporary pain relief
following a sustained, 2-min electrical stimulation.
The
first
clinical
studies
of
implantable nerve stimulators were performed
in 1976 at Johns Hopkins, with the investigators
citing reduced opioid requirement, increased
ability to work, better sleep, improvements in
depressive symptoms, and reduced pain as
potential benefits [5].
Mechanism of Peripheral Nerve
Stimulation
Several mechanisms have been proposed to
explain the effectiveness of PNS. The potential
benefits of counterirritation were reported decades prior to Wall and Sweet’s landmark publication. Temporary pain relief was observed on
withdrawal of many irritating stimuli; irritants
used for this study included heat, ice, and
vibration [6]. The gate control theory of pain
was published later [7]. This theory proposed
that pain nerve fibers of different sizes act as
‘‘gates’’ for different types of sensory information and suggested that one can decrease the
perception of pain by providing competing,
non-painful stimulation through large fiber
neurons to close the small-fiber pain ‘‘gates.’’
Current thinking suggests that, although the
gate control theory is likely involved, it is
unlikely to be the sole mechanism by which
PNS works. Several additional theories have
been proposed, many relating the effects of PNS
to changes in various neuromodulators [8–10].
Despite these lingering questions, PNS continues to be a heavily studied treatment modality
for the management of pain. It has shown
possible effectiveness in the management of
trigeminal neuropathic pain [11–13], chronic
migraine headaches [14–16], complex regional
pain syndrome [17–19] and many other conditions. It is with this background in mind that
we look into the clinical efficacy of PNS and the
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techniques used for the placement and management of various musculoskeletal painful
conditions.

PERIPHERAL NERVE STIMULATION
FOR ACUTE PAIN AFTER SURGERY
Providing optimal postoperative pain control
while improving mobility and time to ambulation, beginning physical therapy, and reducing
overall opioid consumption still poses many
challenges to the anesthesia provider. To
achieve these goals, providers often utilize
multiple approaches consisting of a variety of
multimodal pharmacologic and interventional
approaches. PNS serves as an additional method
to treat post-operative pain while reducing
overall opioid consumption and avoiding difficulties associated with other more-invasive
modalities, including continuous epidural
infusions, perineural stimulators, continuous
peripheral nerve blocks, or even a single shot
nerve block [20]. By utilizing PNS in the treatment of acute postoperative pain, there is an
opportunity to improve recovery time and
reduce overall opioid consumption [21].
Peripheral nerve stimulators are composed of
helically coiled electrical leads, which direct an
applied current to the afferent neurons providing sensory innervation to the painful area. In
theory, the applied current to the peripheral
nerve will alter the large-diameter myelinated
afferent nerve fibers, which interfere with the
central processing of pain signals through
small-diameter afferent fibers at the level of the
spinal cord. Placement of the leads requires
ultrasound guidance and depends on the
specific nerve of the target. Leads are placed at a
distance of 0.5–0.3 cm of the nerve. This is in
contrast to perineural stimulators that are frequently implanted immediately adjacent to and
within the same fascial plane as the target
nerve, which holds a higher risk of neurologic
injury due to needle–nerve contact [21].
Multiple studies have shown success in the
use of peripheral nerve stimulation for acute
post-surgical pain for orthopedic surgery,
including post total knee arthroplasty (TKA)
and anterior cruciate ligament (ACL) surgery.

964

One study reported a case series following eight
patients post TKA showing significant
improvements in Western Ontario and
McMaster
Universities
arthritis
index
(WOMAC). WOMAC is a clinical scale that
reports pain, stiffness, and difficulty with
activities of daily living. On average, subjects in
this study had improvement in WOMAC by
76% and 86% at 6 and 12 weeks, respectively, in
comparison to prior to surgery [22]. Another
case series followed five patients measuring pain
tolerance post-TKA within 2 h after lead
implantation and determination of stimulation
parameters. Following application of stimulation to the femoral or sciatic nerve subjects
showed an average of 63% and 14% reduction
of their pain at rest and active range of motion,
respectively [21]. This study used a small-diameter (0.2-mm), open-coiled, helical electrical
lead with an anchoring wire preloaded within a
20-gauge insertion needle. The timing of the
insertion was postsurgical for all patients,
however, the time after surgery was not within
the 72 h for any of the subjects, which is usually
defined as the acute postoperative period. Time
since surgery varied among subjects from 8 to
97 days. A third study followed five patients
within 60 days post-TKA with knee pain inadequately controlled with oral pain medication.
In this study, leads were inserted 8–58 days
postoperatively, with four out of five subjects
having complete resolution of their pain and an
average pain reduction of 27% and 30% during
passive and active knee range of motion,
respectively [20]. A similar study reported
improvement in pain control and reduced total
opioid requirements post ACL surgery following
femoral nerve stimulation [23]. Although these
studies are promising, the sample sizes are small
and larger studies are warranted.
There was a study that looked at acute postoperative pain control following upper extremity surgery, however, it was a proof-of-concept
study to look at lead implantation sites and to
see if this could be feasible in the postoperative
period. Leads were placed using ultrasound
guidance intended to target the suprascapular
nerve or brachial plexus, preoperatively.
Patients received stimulation in 5-min periods
or a sham followed by a 5-min crossover period
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and then continuous stimulant until the leads
were removed between postoperative days
14–28. This study found that it was feasible,
however, the analgesia immediately following
the surgery did not appear to be as potent as
local anesthetic-based peripheral nerve blocks
[24]. This study showed that PNS could be useful in the possible reduction of opioid use in the
postoperative period.
In addition to improvement in pain control
and disability, the relative size of PNS devices
allows the user to wear a small pulse generator
comfortably in an ambulatory setting. This is
much more feasible than requiring the user to
have an attached infusion pump and to carry a
local anesthetic reservoir [20]. Additionally,
typical post-operative pain in extremities will
outlast the length of pain relief provided by a
continuous peripheral nerve block, which may
only be utilized for 3–4 days postoperatively
[21, 25]. Continuous local anesthetic infusion
also induces sensory and motor blockade, while
PNS does not produce these effects. These procedures are also more invasive, costly, hold a
higher risk of infection, and may prolong the
time to ambulation and increase the risk of falls
in comparison to peripheral nerve stimulators
[20]. These continuous infusions would also
increase the number of days in the hospital,
which goes against the current trend of trying
to reduce the days spent in the hospital after
surgery.
Among the range of potential therapies in
the acute setting and PNS provides adequate
therapy while avoiding challenges and possible
complications of more-invasive techniques.
Related to the relative size of PNS devices and
small associated risks, PNS devices can be
applied feasibly to treat acute postoperative
pain immediately following surgery and
extending to the ambulatory setting. By introducing PNS to the spectrum of analgesic treatments, patients can experience better overall
outcomes by improving mobility, time to
ambulation, and reducing overall opioid consumption, while adequately treating pain [20].
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SHOULDER
Chronic shoulder pain is a common condition
with an estimated prevalence of 20–33%, with
40% of all cases proceeding longer than 1 year
[26, 27]. Many studies have investigated the
utility of PNS for the management of chronic
shoulder pain. Hemiplegic shoulder pain (HSP),
a condition causing decreased mobility and
increased pain in stroke patients, is the most
frequently studied chronic shoulder pain diagnosis in terms of response to PNS. Other diagnoses commonly implicated in shoulder pain
include rotator cuff disorders, adhesive capsulitis, shoulder instability, and shoulder arthritis
[26, 28]. Current interventional shoulder pain
relief options, such as medications, steroid
injections, physical therapy, and acupuncture,
are available but are limited as many of these
only provide short-term relief for long-term
symptoms. It is this conundrum that drives the
search for alternative shoulder pain treatment
options.
Anatomy and Placement Technique
Innervation of the shoulder joint primarily
comes from two nerves: the axillary and
suprascapular nerves [29]. The suprascapular
nerve provides sensory innervation to the posterior glenohumeral joint and motor to the
supraspinatus and infraspinatus muscles. The
deltoid and teres minor are innervated by the
axillary nerve. These two nerves are the primary
focus of most studies investigating the use of
PNS for the management of shoulder pain.
Nerves can be targeted for PNS using a variety of techniques. Open surgical placement can
be performed by dissecting down to the nerve in
question and placing a lead alongside the nerve
for stimulation. Nerve-stimulation trials sometimes precede permanent stimulator placement,
although this practice is of questionable benefit
in patients with shoulder pain as patients with
failed trials have been observed to benefit from
the placement of a permanent peripheral nerve
stimulator [30]. Open surgical placement is also
associated with higher rates of post-operative
pain, a concerning finding in patients being
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treated for chronic pain. The major benefit of
percutaneous placement is that it is faster and
less traumatic. Usage is limited by the need for
superficial nerve targets, higher rates of postplacement lead migration, and susceptibility to
equipment malfunctions [30, 31]. Ultrasoundguided lead placement has been studied for the
shoulder, which provides an alternative to open
placement for deeper nerve structures. The
suprascapular and axillary nerves can be targeted from any location throughout their
courses, although the suprascapular notch and
the posterior humerus, respectively, are the
most common locations picked [30, 32, 33]. For
either nerve, a needle can be advanced under
ultrasound guidance until it is just past the
nerve. Once the target is reached, a guide can be
placed to facilitate lead placement, and the
needle is removed; a dilator is used to open the
target space. The lead can be placed through the
dilator. This technique reliably places leads
within 0.5 cm of the target nerve in most
patients [33]. There is a problem of placing the
lead too close to the nerve as it may lead to
motor stimulation of the nerve.

PERIPHERAL NERVE STIMULATION
FOR BACK PAIN
The treatment of chronic lower back pain
(CLBP) consists of a continuum of pharmacologic and procedural therapies. The use of
multimodal analgesic medications, rehabilitation, and percutaneous interventions have been
clinically shown to reduce total opioid consumption and better overall pain control. PNS
serves as one of the potential non-pharmacologic therapies to treat CLBP along with physical therapy, application of transcutaneous
electrical neurostimulation (TENs) units,
radiofrequency ablation, epidural steroid injections, permanently implanted neurostimulators, and surgery [34]. Due to PNS having fewer
associated risks and relative feasibility, it can
serve as an effective option prior to the application of permanently implanted systems or
even surgical intervention [35].
Another way to treat CLBP is spinal cord
stimulators (SCS), which work by activating
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large, rapidly conducting fibers [36]. Spinal cord
stimulation involves the generation of electric
fields, which are conducted between metal
contacts residing in the epidural space. These
applied fields change the electric potential
across membranes leading to one or more
action potentials depending on the axon’s
diameter, myelination status, and electric
threshold [36]. In North et al., patients who
were treated with spinal cord stimulators had a
50% or greater pain relief and satisfaction [36];
while in Kumar et al., spinal cord stimulators
had greater success compared to conservative
medical management [36]. The study by Kemler
et al. compared physical therapy to a conventional spinal cord stimulator and found that
stimulators were superior to physical therapy in
patients suffering from complex regional pain
syndrome [36].
The proposed mechanism of action is
through the modulation of central sensitization. More specifically, the applied current
interferes with processing afferent pain signaling fibers to the spinal cord and central nervous
system through the commonly accepted gate
mechanism [34]. Anatomic targets of PNS
include the medial branches of the dorsal rami.
Leads are placed under ultrasound guidance
adjacent to the medial branches using known
anatomical landmarks as the dorsal rami exits
the intervertebral foramen. Confirmation of the
correct position of lead placement requires
stimulating the probe into the tissue with
selective activation of the lumbar multifidus
and comfortable contractions overlapping the
region of pain [34]. One study reported an
optimal lead depth of 10–12 mm from the surface of the skin to maximize the target sensation
for CLBP [37]. Stimulators can also have programmable settings that allow each individual
to receive an optimal strength of stimulation
while still providing comfortable sensations
[34].
PNS can serve as a preferred option for the
treatment of back pain prior to implanting
permanent spinal cord stimulation and surgery.
Due to the placement of leads near the spinal
cord, spinal cord stimulation (SCS) has more
complications that are consequential and have
a higher associated expense. For these reasons,
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SCS is typically reserved as a treatment of last
resort. Additionally, more invasive surgical
procedures, including spinal fusion and disc
replacement, do not always adequately improve
pain or reduce disability. For these cases, there
remains a therapeutic gap before opting for
treatments with higher associated risks [34].
Utilizing PNS early in treatment has been
suggested to improve patient outcomes by
potentially reducing the number of hospitalizations, clinic visits, and reducing overall opioid consumption [34]. Providing this option
gives the patient an opportunity to avoid the
need for a permanently implanted system or
surgery prematurely or altogether in chronic
back pain. PNS shows promise to function as an
early and effective option in the treatment
continuum while reducing pain, opioid use,
and disability [35, 38].

PERIPHERAL NERVE STIMULATION
FOR KNEE PAIN
Chronic knee pain and knee pain following
surgery are commonly treated with a range of
pharmacologic, interventional, rehabilitative
methods. PNS provides an additional line of
therapy in the treatment of both post-operative
and chronic knee pain [20, 39]. The addition of
PNS to the spectrum of therapeutic options
gives patients the ability to utilize non-pharmacological pain control sooner before opting
for more invasive interventions. Its application
can additionally reduce overall opioid consumption and provide better overall pain relief.
While PNS does not completely eradicate pain
in all refractory cases, it can serve as a bridge in
the gap in therapy between pharmacologic
modalities and more-invasive interventions
[21].
Similar to the application of PNS stimulator
to other regions of pain, the implanted leads
target the large diameter myelinated afferent
nerve fibers, which interfere with central processing of pain signals through small-diameter
afferent fibers in the spinal cord and central
nervous system [20]. Depending on the origin
of knee pain, common nerve targets include the
femoral and the sciatic nerve. Leads are placed
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under ultrasound guidance and usually aim to
place the lead between 0.5 and 3.0 cm from the
nerve. Since the generated current can be
applied at a distance, placement of the leads
avoids the associated risk of peripheral nerve
damage.
One potential risk of PNS placement is lead
migration. Reducing the risk of lead migration
prevents failure of providing analgesia, activation of cutaneous pain fibers. Avoiding lead
placement across large joints such as the knee or
hip can help prevent this risk [40]. Additionally,
the helical design of the leads limits the risk of
lead migration by providing a more flexible
composition that allows the wire to stretch
when the subject moves. This feature also promotes tissue ingrowth between the coils, providing additional support. Additionally, the
design can even decrease the risk of infection to
0.03 per 1000 indwelling days [21]. In short, the
design can help decrease the risk of both infection and lead migration.
In the setting of acute, post-operative knee
pain, PNS can provide specific advantages in
comparison to continuous peripheral nerve
blockade and epidural local anesthetic infusions. Epidural local anesthetic infusions can
provide pain relief for 3–4 days due to the risk of
infection and local anesthetic reservoir exhaustion. Epidural infusions are further associated
with urinary retention, motor weakness,
hypotension, and risk of epidural hematoma
[20]. In comparison to continuous peripheral
nerve blocks, PNS devices are lightweight and
can be worn comfortably with a stimulator
attached either to the ipsilateral limb or the
abdomen. Continuous blocks are also associated
with dislodgement, fluid leakage, and require
the patient to have attached infusion pumps
and anesthetic reservoirs [23].
Peripheral nerve stimulators have also shown
efficacy in the treatment of chronic and postoperative knee pain. While providing adequate
pain relief, peripheral nerve stimulators are less
invasive, costly, and have less associated risk of
infection than other traditional approaches.
Neurostimulation avoids potential risks of
common pharmacologic and invasive treatments and can serve a key role in the management of knee pain.
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CLINICAL STUDIES: SAFETY
AND EFFICACY
Peripheral nerve stimulators have been studied
for use in patients of several different types of
pain. In a study where 28 lower-extremity
amputees with post-amputation pain were
enrolled, subjects underwent ultrasound-guided
implantation of the percutaneous leads, and
patients either received peripheral nerve stimulators or placebo [41]. This was a crossover
study in which the placebo group received a
peripheral nerve stimulator for four additional
weeks [41]. In this study, a significantly greater
number of patients who received peripheral
nerve stimulators demonstrated 50% or more
reduction in postamputation pain during the
1–4 weeks as compared to placebo [41].
Back Pain
Multiple studies have reported improvements in
overall pain control, disability, and opioid
consumption following PNS implantation for
the treatment of CLBP. One case series followed
nine patients and measured their reported pain
scores following PNS lead placement. This
report showed a significant, sustained level of
therapeutic relief of CLBP and disability with
clinical reductions of C 50% in two-thirds of
patients for at least 12 months following lead
removal [34]. Additionally, a prospective multicenter study following 118 patients during
therapy with PNS showed significant improvement in all pain and quality-of-life measures
and an overall reduction in the use of opioids,
non-steroidal anti-inflammatory drugs, and
anticonvulsants [42]. A third study followed 100
patients with a variety of chronic pain syndromes and measured pain, complications, disability, and depression outcomes following PNS
treatment. One cohort in this study showed
significant improvement to pain and disability
following receiving lumbosacral PNS as measured by the Oswestry Disability Index without
any long-term reported complications [43].
In another study with patients who have
CLBP, the subjects received percutaneous
peripheral nerve stimulator leads that targeted
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the medial branch of the dorsal ramus in the
region of lower back pain [44]. The leads
remained in place for 30 days of therapy. Even
after the removal of the peripheral nerve stimulator leads, there were sustained long-term
benefits of the peripheral nerve stimulator leads
in treating chronic lower back pain. Patients
showed improvement in pain through a reduction in pain and disability and sustained
reduction in the use of analgesic medication;
this continued long term at the 4-month follow-up visit [44]. Subjects also reported clinically significant reductions in disability (based
on the Oswestry Disability Index), pain interference, and the patient’s global impression of
change.
Knee Pain
Percutaneous peripheral nerve stimulation has
been studied with the intention to control the
often severe, long-lasting postoperative pain
following total knee arthroplasty [45]. In a
study of patients undergoing primary, unilateral
total knee arthroplasty, the patients received
both a femoral and sciatic open coil percutaneous leads that were placed 1 week prior to
surgery. Although the study was small (n = 7),
the majority of subjects using percutaneous
peripheral nerve stimulation had well-controlled postoperative pain during the first week
following total knee arthroplasty. In six out of
seven patients, pain was well controlled even
4 weeks after total knee arthroplasty. Additionally, four out of the seven subjects studied had
such well-controlled pain that opioid use was
discontinued in the first week. One of the four
subjects did not even require opioids during the
duration of therapy. The study suggests that
perioperative percutaneous peripheral nerve
stimulators may enable patients to experience
reduced post-operative pain, earlier cessation of
opioid use, and accelerated functional recovery
following the total knee arthroplasty. However,
it is important to note that the study was limited by small size (n = 7), and future studies
should be designed to further investigate the
risks and benefits of the above intervention
[45].

While PNS for knee pain has mostly been
studied in acute postoperative knee pain, there
is also evidence that PNS can be used among
other therapies for chronic knee pain. One
study showed effective pain relief using PNS for
treatment of chronic intractable knee pain following TKA. The patients participating in the
study had chronic knee pain for greater than
1-year post-surgery, which was intractable to
NSAIDs, physical therapy, TENS unit, oral antidepressants, opioids, and surgical revisions. This
study showed a significant improvement in
functional capacity and reduction in pain visual
analog scale scores [40]. Another study reported
the effectiveness of PNS in improving chronic
knee pain following an 8-week course receiving
PNS therapy three times a week. This study
showed improvement in pain, stiffness, and
physical function utilizing the Western Ontario
and McMaster Universities arthritis index
(WOMAC) and the short-form 36-item health
survey (SF-36), suggesting its effectiveness to
treat chronic knee pain [39].
Shoulder Pain
Hemiplegic shoulder pain is a common condition that affects stroke survivors within the first
12 months of their stroke [46]. This hemiplegic
shoulder pain is associated with poor rehab
outcomes and interferes with activities of daily
living, which leads to very poor quality of life
[46] and poor functional outcomes [47]. There is
a study that examined the effects of peripheral
nerve stimulation, which focused on hemiplegic shoulder pain in stroke survivor patients.
The study explored the safety and feasibility of a
single lead peripheral nerve stimulator, which
was fully implanted and placed so that it stimulated the axillary nerve of the affected shoulder, leading to contractions of the middle and
posterior deltoid muscles for 6 h a day for
3 weeks [46]. Around 57% of patients enrolled
in the trial had a two-point reduction in pain
during active stimulation [46]. Patients experienced improvement in pain-free external range
of motion and reduction in pain and pain
interference with no serious adverse events
related to the device or the procedure [46].
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Another randomized controlled trial was
performed to compare physical therapy to
peripheral nerve stimulation on shoulder
biomechanics in patients with chronic hemiplegic shoulder pain [47]. The study focused
more on the effects peripheral nerve stimulators
had on the patient’s shoulder strength, range of
motion, and motor function. The purpose of
the study was to determine if there is a correlation between pain reduction and biomechanical outcomes [47]. Participants were
randomized to either receive a 3-week treatment with a single-lead peripheral nerve stimulator or physical therapy (PT). Outcomes were
measured at baseline and weeks 1, 4, 12, and 16
[47]. Participants were approximately split in
half, with 13 patients assigned to a peripheral
nerve stimulator and 12 assigned to PT sessions
[47]. Patients in the PT treatment group
received 8 h of outpatient PT over a 4-week
period from a licensed therapist, and they also
were advised to perform a home exercise program as well. Interestingly, the results of the
study suggested that both peripheral nerve
simulators and physical therapy were associated
with improvements in biomechanics but that
biomechanics alone did not account for the
greater pain relief in patients with PNS compared to physical therapy [47]. There are
numerous reasons for this finding, with the first
being that shoulder biomechanics may not be
as important in the maintenance of chronic vs.
acute hemiplegic shoulder pain [47]. The study
above may also have been too small of a population size to detect a difference in shoulder
biomechanics [47].

in chronic pain. Early investigations suggest
that nerve stimulators are safe to use for up to
18 years, with wide differences in biostability
noted for stimulators placed in different locations [48–51].
The utility of newer technology also requires
further investigation. New techniques for
placement of peripheral nerve stimulation will
likely open the possibility of targeting deeper
neural structures for PNS. Smaller devices create
opportunities to use PNS for smaller nerves that
the modern stimulators are able to effectively
stimulate. This widens the array of possible
chronic pain syndromes for which PNS can
provide relief of symptoms not well managed by
traditional medical and physical therapies.
PNS can play a large role in the future of
chronic pain management. Although there is
still much to learn in regard to specific mechanisms, patient selection, and long-term safety,
early results have shown promise. Currently,
many devices placed for treatment of chronic
pain are placed as an off-label use of the device.
Obtaining this important safety data is an
important next step. More information allows
for expansion of the number of relevant diagnoses for which this therapy can be applied. It
also allows for standardized safety protocols to
be developed to optimize short-term and longterm safety. Through further investigation, a
useful adjunct for management of chronic pain
can be developed with PNS.

CONCLUSIONS

Funding. No funding or sponsorship was
received for this study or publication of this
article.

PNS has shown great promise in the management of a wide variety of common musculoskeletal pains. Several trials have predicted its
effectiveness without the side effects and could
reduce the need for potentially addictive medications given for management of pain. Further
studies are needed as the long-term risks and
benefits of PNS have not been well studied as
most information available on the effectiveness
of PNS is based on shorter-term improvements
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